The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors

The β(3)‐adrenoceptor agonist mirabegron is approved for use for overactive bladder and has been purported to be useful in the treatment of obesity‐related metabolic diseases in humans, including those involving disturbances of glucose homeostasis. We investigated the effect of mirabegron on glucose...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacol Res Perspect
Hlavní autoři: Dehvari, Nodi, Sato, Masaaki, Bokhari, Muhammad Hamza, Kalinovich, Anastasia, Ham, Seungmin, Gao, Jie, Nguyen, Huong T. M., Whiting, Lynda, Mukaida, Saori, Merlin, Jon, Chia, Ling Yeong, Wootten, Denise, Summers, Roger J., Evans, Bronwyn A., Bengtsson, Tore, Hutchinson, Dana S.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7437350/
https://ncbi.nlm.nih.gov/pubmed/32813332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.643
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky